Parallel Advisors LLC Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Parallel Advisors LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,165 shares of the medical research company’s stock after selling 67 shares during the period. Parallel Advisors LLC’s holdings in IQVIA were worth $1,801,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in IQV. Raymond James Financial Inc. bought a new stake in IQVIA during the fourth quarter valued at $236,120,000. FMR LLC boosted its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in IQVIA during the third quarter valued at $147,683,000. JPMorgan Chase & Co. lifted its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.9 %

IQV stock opened at $188.45 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34. The business’s 50 day moving average price is $196.06 and its two-hundred day moving average price is $209.52. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $33.23 billion, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Citigroup dropped their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Barclays dropped their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Finally, UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.